INTRON A® (interferon alfa-2b)

Drug INTRON A® interferon alfa-2b intron A Overview This is a summary of the European public assessment report (EPAR) for IntronA. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for IntronA. How is Intron A […]

JYLAMVO® (methotrexate)

Drug JYLAMVO® methotrexate Jylamvo Overview Jylamvo is an anti-inflammatory and cancer medicine used to treat the following conditions:  active rheumatoid arthritis (a disease causing inflammation in joints) in adults; severe juvenile idiopathic arthritis (inflammation of joints in children) in patients from 3 years of age when NSAIDs (non-steroidal anti-inflammatory drugs) have not worked well enough; […]

ICLUSIG® (ponatinib)

Drug ICLUSIG® ponatinib Iclusig Overview Iclusig is a cancer medicine that contains the active substance ponatinib. It is used to treat adults with the following types of leukaemia (cancer of the white blood cells): chronic myeloid leukaemia (CML) in its different stages known as chronic, accelerated and blast phases; acute lymphoblastic leukaemia (ALL) in patients who are […]

SPRYCEL® (dasatinib)

Drug SPRYCEL® dasatinib Sprycel Overview Sprycel is a cancer medicine. It is used to treat adults with the following types of leukaemia (cancer of the white blood cells): chronic myeloid leukaemia (CML) in the ‘chronic’ phase in newly diagnosed patients who are ‘Philadelphia chromosome positive’ (Ph+). In CML, granulocytes (a type of white blood cell) […]

EVOLTRA® (clofarabine)

Drug EVOLTRA® clofarabine Evoltra Overview This is a summary of the European public assessment report (EPAR) for Evoltra. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Evoltra. How […]

BLINCYTO® (blinatumomab)

Drug BLINCYTO® blinatumomab Blincyto Overview Blincyto is a medicine used to treat a blood cancer called B-precursor acute lymphoblastic leukaemia (ALL) in patients above 1 year of age when the cancer has come back (relapsed) or has not improved with previous treatment (refractory). Blincyto is also used in adults who have been treated for B-precursor […]

ONCASPAR® (pegaspargase)

Drug ONCASPAR® pegaspargase Oncaspar Overview Oncaspar is a cancer medicine used in adults and children to treat acute lymphoblastic leukaemia (ALL), a cancer of white blood cells called lymphoblasts. Oncaspar is used in combination with other cancer medicines. It contains the active substance pegaspargase. How is Oncaspar used? Oncaspar is normally given every 14 days by injection […]

SPECTRILA® (asparaginase)

Drug SPECTRILA® asparaginase Spectrila Overview This is a summary of the European public assessment report (EPAR) for Spectrila. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Spectrila. For practical information about using Spectrila, […]

ATRIANCE® (nelarabine)

Drug ATRIANCE® nelarabine Atriance Overview This is a summary of the European public assessment report (EPAR) for Atriance. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Atriance.   How is Atriance used? Atriance is […]

GLIVEC® (imatinib)

Drug GLIVEC® Pembrolizumab Glivec Overview This is a summary of the European public assessment report (EPAR) for Glivec. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Glivec. How is Glivec used? Glivec treatment should […]